Crystal Pharmatech

How does polymorphism impact drug development? As we dive into Section 2 of Crystal Classroom, Screening Protocols, Subject Matter Expert, Maili Heshuote, details polymorphism topics including: 🔹 Polymorphism and its influence 🔹 Regulatory implications 🔹 Technological advancements related to polymorphism Subscribe on YouTube to keep up with the series: https://lnkd.in/eVgyBysW #CrystalPharmatech #CrystalClassroom #Chemistry #PharmaceuticalScience #CMC #Biotech #DrugDevelopment #Research #Technology #API #CRO #CDMO

Another busy month for our team across the US. It was a pleasure to connect with industry colleagues to discuss the latest advancements in pharmaceutical science and at Crystal Pharmatech. #CrystalPharmatech #PharmaceuticalScience #CMC #Biotech #DrugDevelopment #Formulation #Pharma #Research #Technology #API #CRO #CDMO

Webinar Highlight: Applying AI to development and manufacturing Kevin Bittorf, Ph.D., and Keith Parent detail how AI can help with drug development and manufacturing with regard to: 🔹 Quality control 🔹 Batch monitoring 🔹 Predictive maintenance 🔹 Process optimization 💡 View the full recording of last month’s webinar at: https://lnkd.in/d6yNbZei 📅 Register for our next webinar on November 20th at 2pm EST: https://lnkd.in/dDRGcm5T #CrystalPharmatech #FormulationForum #PharmaceuticalScience #CMC #Biotech #DrugDevelopment #Formulation #Pharma #Research #Technology #AI #API #CRO #CDMO

What considerations are important for a successful formulation development? Senior Scientist, Sawani Talekar, Ph.D. introduces Part 2 of the Formulation Classroom as we dive into drug product formulation considerations. 🔹 Aspects of a Successful Formulation 🔹 Quality Target Product Profile (QTPP) 🔹 Additional Considerations Subscribe on YouTube to follow the Formulation Classroom series: https://lnkd.in/eCuMSN_M Crystal Pharmatech #CrystalPharmatech #FormulationClassroom #Formulation #Chemistry #PharmaceuticalScience #CMC #Biotech #DrugDevelopment #Research #Technology #API #CRO #CDMO

📅 We’re excited to bring our executive leadership and subject matter experts to Salt Lake City and discuss small molecule research, development, and manufacturing at American Association of Pharmaceutical Scientists (AAPS) | @aapscomms PharmSci 360. Join us at Booth 3139 to discuss topics including: 🔹 Developability Assessment 🔹 API form and solid-state research 🔹 Formulation development 🔹 Clinical and commercial manufacturing 🔹 Biologics analytical services Robert Wenslow Yongqiang Li, PhD Decheng Ma Ridwan Islam, M. Pharm., Ph.D. Candoo Pharmatech Company Inc. Crystal Formulation Services, a member of Crystal Pharmatech #CrystalPharmatech #PharmaceuticalScience #CMC #Biotech #DrugDevelopment #Formulation #Pharma #Research #Technology #API #CRO #CDMO

Webinar Highlight: How can AI save money and speed up development time? Kevin Bittorf, Ph.D., and Keith Parent answer this question from our moderator, Ridwan Islam, M. Pharm., Ph.D. Last month’s webinar discussed how drug developers can implement and utilize AI. 💡 View the full recording at: https://lnkd.in/e8SeW5Pw 📅 Register for our next webinar on November 20th at 2pm EST: https://lnkd.in/eh-g9UY7 #CrystalPharmatech #FormulationForum #PharmaceuticalScience #CMC #Biotech #DrugDevelopment #Formulation #Pharma #Research #Technology #AI #API #CRO #CDMO

📅 Connect with our formulation experts at the Formulation & Delivery US 2024 conference in San Diego from October 16-17. Hear from Xiaoxia (Jessica) Chen, Ph.D. as she presents “First in Human (FIH) Tablet Development for an Amorphous Unstable Prodrug with Enteric Coating Using an API Sparing Approach”. Decheng Ma, Ph.D., CEO of Crystal Formulation Services, a member of Crystal Pharmatech, will also be available to discuss our latest capabilities for developing and manufacturing CTM with minimal lead times and very cost competitive options. 💡 Abstract: This presentation will explore the formulation and development process of First-In-Human (FIH) enteric-coated tablets at three dose strengths for an amorphous prodrug highly susceptible to hydrolysis under both acidic and basic conditions. We will delve into the scientific approaches employed to mitigate degradation pathways, ensure product stability through carefully selected excipients and optimized manufacturing techniques, and how material science-based approaches can lead to successful FIH product development within tight timelines. #CrystalPharmatech #PharmaceuticalScience #CMC #Biotech #DrugDevelopment #Formulation #Pharma #Research #Technology #API #CRO #CDMO

Concerned about mRNA-LNP integrity during international shipping? Strategic partners, Crystal Bio and CATUG, combined efforts to evaluate the effects of mRNA-LNP integrity during international shipping to compare data between shipping sites for: 🔹 Size with distribution 🔹 Encapsulation 🔹 Purity For more information, visit: https://lnkd.in/eHEb33rN #CrystalBio #CATUGCrystal #CrystalPharmatech #CATUG #PharmaceuticalScience #Biologics #CMC #Biotech #DrugDevelopment #Research #Technology #API #CRO #CDMO

Whether it’s a fast-crystallizing SDI or (not-so-)simple compounding, it is not uncommon to encounter challenges during formulation development and CTM manufacture. This case study series dives into formulation challenges that biotechs needed help solving as they raced to the clinic. This series is hosted by Robert Wenslow, Ph.D., Co-Founder of Crystal Pharmatech. Dr. Wenslow details the issues and how Crystal Pharmatech addressed them to deliver a successful Phase I CTM manufacture. Each video can be found on YouTube at: https://lnkd.in/eWUCnPeG Crystal Formulation Services, a member of Crystal Pharmatech #CrystalPharmatech #FormulationForum #PharmaceuticalScience #CMC #Biotech #DrugDevelopemnt #Formulation #Pharma #Research #Technology #API #CRO #CDMO

📅 The Drug Discovery Strategic Summit is a promising opportunity to dive into the early insights that can be derived from a material-sparing approach. Join us in San Francisco as Robert Wenslow, Ph.D. presents “The Best Use of 10mg: Achieve CMC success through a unique optimization of compound benchwork and computational analysis”. He will be joined by Subject Matter Expert, Ridwan Islam, M. Pharm., Ph.D. on October 9-10 to meet with drug innovators on the west coast. 💡 Abstract: Small Molecule drug discovery scientists have been trained to believe that they need gram scale quantities of API to determine CMC properties such as solubility, oral absorption, and salt selection to understand the formulation strategy. Crystal Pharmatech will unveil its proven approach to understanding the developmental risks through focused laboratory work and the most advanced computational approaches. You will understand how, with only 10mg of material, you can move from late lead-op to FIH with a line-of-sight of your compound’s development path and significantly enhance your probability of success in the clinic. #CrystalPharmatech #PharmaceuticalScience #CMC #Biotech #DrugDevelopment #Formulation #Pharma #Research #Technology #API #CRO #CDMO